HRP960312B1 - NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) - Google Patents

NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)

Info

Publication number
HRP960312B1
HRP960312B1 HR960312A HRP960312A HRP960312B1 HR P960312 B1 HRP960312 B1 HR P960312B1 HR 960312 A HR960312 A HR 960312A HR P960312 A HRP960312 A HR P960312A HR P960312 B1 HRP960312 B1 HR P960312B1
Authority
HR
Croatia
Prior art keywords
phenylamino
fluorophenyl
pyrrole
dihydroxy
delta
Prior art date
Application number
HR960312A
Other languages
English (en)
Inventor
Min Lin
Dieter Schweiss
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21696097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP960312(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HRP960312A2 publication Critical patent/HRP960312A2/hr
Publication of HRP960312B1 publication Critical patent/HRP960312B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
HR960312A 1995-07-17 1996-07-03 NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) HRP960312B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US145395P 1995-07-17 1995-07-17

Publications (2)

Publication Number Publication Date
HRP960312A2 HRP960312A2 (en) 1998-02-28
HRP960312B1 true HRP960312B1 (en) 2001-10-31

Family

ID=21696097

Family Applications (1)

Application Number Title Priority Date Filing Date
HR960312A HRP960312B1 (en) 1995-07-17 1996-07-03 NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)

Country Status (37)

Country Link
US (1) US6274740B1 (cs)
EP (1) EP0839132B1 (cs)
JP (1) JP4064459B2 (cs)
KR (1) KR100400805B1 (cs)
CN (1) CN1087289C (cs)
AR (1) AR002849A1 (cs)
AT (1) ATE199542T1 (cs)
AU (1) AU700794B2 (cs)
BG (1) BG63631B1 (cs)
BR (1) BR9609714A (cs)
CA (1) CA2220455C (cs)
CO (1) CO4700441A1 (cs)
CZ (1) CZ289421B6 (cs)
DE (1) DE69611999T2 (cs)
DK (1) DK0839132T5 (cs)
EA (1) EA000625B1 (cs)
EE (1) EE03605B1 (cs)
ES (1) ES2156997T3 (cs)
GE (1) GEP20002027B (cs)
GR (1) GR3035859T3 (cs)
HR (1) HRP960312B1 (cs)
HU (1) HU220343B (cs)
IL (1) IL122161A (cs)
IN (1) IN185276B (cs)
MX (1) MX9708959A (cs)
NO (1) NO309322B1 (cs)
NZ (1) NZ313008A (cs)
PE (1) PE1698A1 (cs)
PL (1) PL191017B1 (cs)
PT (1) PT839132E (cs)
RO (1) RO120069B1 (cs)
SI (1) SI0839132T1 (cs)
SK (1) SK283204B6 (cs)
UA (1) UA50743C2 (cs)
UY (1) UY24286A1 (cs)
WO (1) WO1997003960A1 (cs)
ZA (1) ZA966043B (cs)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
IN191236B (cs) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
US6646133B1 (en) 2000-10-17 2003-11-11 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
HU226640B1 (en) * 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
CA2427255A1 (en) * 2000-11-16 2002-06-06 Teva Pharmaceutical Industries Ltd. Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta. -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CZ20032019A3 (cs) 2000-12-27 2003-10-15 Ciba Specialty Chemicals Holding Inc. Krystalické formy Atorvastatinu
WO2002057228A1 (en) * 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (cs) * 2001-04-11 2003-08-09 Cadila Heathcare Ltd
WO2003004470A1 (en) 2001-06-29 2003-01-16 Warner-Lambert Company Llc Crystalline forms of 'r-(r*,r*)!-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
US7361772B2 (en) 2001-08-16 2008-04-22 Biocon Limited Process for the production of atorvastatin calcium
AU2001284385A1 (en) 2001-08-31 2003-03-10 Morepen Laboratories Ltd. An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CZ296967B6 (cs) 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
AU2002247944B2 (en) * 2002-03-18 2009-05-21 Biocon Limited Amorphous Hmg-CoA reductase inhibitors of desired particle size
RU2309141C2 (ru) * 2002-03-18 2007-10-27 Байокон Лимитид АМОРФНЫЕ ИНГИБИТОРЫ ГМГ-КоА-РЕДУКТАЗЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
WO2003099785A1 (en) * 2002-05-28 2003-12-04 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
US7179942B2 (en) 2002-07-05 2007-02-20 Bicon Limited Halo-substituted active methylene compounds
JP2006503024A (ja) * 2002-09-03 2006-01-26 モレペン、ラボラトリーズ、リミテッド Ｖｉ型アトルバスタチンカルシウムまたはその水和物
AU2004228607B2 (en) 2003-04-11 2011-01-27 Lek Pharmaceuticals D.D. Process for the preparation of amorphous calcium salt of atorvastatin
AU2003231926A1 (en) 2003-04-22 2004-11-19 Biocon Limited NOVEL PROCESS FOR STEREOSELECTIVE REDUCTION OF ss-KETOESTERS
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
AU2003272080A1 (en) 2003-09-18 2005-04-06 Biocon Limited Novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
CZ298382B6 (cs) * 2004-03-10 2007-09-12 Zentiva, A. S. Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace
ATE545629T1 (de) * 2004-03-17 2012-03-15 Ranbaxy Lab Ltd Verfahren zur herstellung von atorvastatin- calcium in amorpher form
BRPI0510713A (pt) 2004-05-05 2007-11-20 Pfizer Prod Inc formas de sal de ácido [r-(r*,r*)]-2-(4-fluorofenil)-beta, delta-diidróxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)ca rbonil]-1h-pirrol-1- heptanóico
CA2573969C (en) * 2004-07-16 2014-02-04 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
US7645888B2 (en) 2004-08-27 2010-01-12 Biocon Limited Process for the production of amorphous atorvastatin calcium
KR20070106680A (ko) * 2004-09-30 2007-11-05 닥터 레디스 레보러터리즈 리미티드 비정질 아토르바스타틴 칼슘
ES2272206T1 (es) * 2004-10-18 2007-05-01 Teva Pharmaceutical Industries Ltd. Procedimiento para la preparacion de la atorvastatina hemicalcica amorfa por disolucion de la sal en un disolvente organico que es una mezcla de un alcohol, y una cetona y/o un ester y eliminacion del disolvente.
NZ554541A (en) * 2004-10-28 2011-01-28 Warner Lambert Co Process for forming amorphous atorvastatin
CA2588216A1 (en) * 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
US20090088465A1 (en) * 2004-12-02 2009-04-02 Stephen Craig Dyar Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
US20080108664A1 (en) * 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
CA2640573A1 (en) * 2006-03-01 2007-09-13 Michael Pinchasov Process for preparing a crystalline form of atorvastatin hemi-calcium
WO2008053312A2 (en) * 2006-11-02 2008-05-08 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its intermediate
US7834195B2 (en) 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
EP2185527A2 (en) * 2007-07-11 2010-05-19 Actavis Group PTC EHF Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
US20090124817A1 (en) * 2007-11-09 2009-05-14 The Industry & Academic Cooperation In Chungnam National University Process for Preparing Amorphous Atorvastatin Calcium Nanoparticles
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
WO2010066846A2 (en) * 2008-12-11 2010-06-17 Dsm Ip Assets B.V. Method for the isolation of atorvastatin
WO2010069593A1 (en) 2008-12-19 2010-06-24 Krka, D. D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
IL128862A (en) 1995-07-17 2007-12-03 Warner Lambert Co [R - (R * R *)] - 2 - (4 - fluorophenyl) - ß, d - dihydroxy - 5 - (1 - methyl - ethyl) 3 - phenyl - 4 - [(phenamino) carbonyl)] - 1H - Pyrol - 1 - Patenoic acid Hydrogen salt Hydrogen crystalline (Atorostatin) Crystalline hydrate

Also Published As

Publication number Publication date
PE1698A1 (es) 1998-02-19
MX9708959A (es) 1998-03-31
DE69611999T2 (de) 2001-07-26
BR9609714A (pt) 1999-02-23
CA2220455C (en) 2002-09-24
IL122161A0 (en) 1998-04-05
BG63631B1 (bg) 2002-07-31
ES2156997T3 (es) 2001-08-01
CA2220455A1 (en) 1997-02-06
HK1018054A1 (en) 1999-12-10
AR002849A1 (es) 1998-04-29
HUP9903017A3 (en) 2001-01-29
EA199800128A1 (ru) 1998-08-27
EP0839132A1 (en) 1998-05-06
SI0839132T1 (cs) 2001-06-30
CZ289421B6 (cs) 2002-01-16
GR3035859T3 (en) 2001-08-31
NO309322B1 (no) 2001-01-15
BG102188A (en) 1998-08-31
WO1997003960A1 (en) 1997-02-06
UA50743C2 (uk) 2002-11-15
RO120069B1 (ro) 2005-08-30
JP4064459B2 (ja) 2008-03-19
NO980209D0 (no) 1998-01-16
AU700794B2 (en) 1999-01-14
CO4700441A1 (es) 1998-12-29
CN1190956A (zh) 1998-08-19
JPH11510486A (ja) 1999-09-14
NZ313008A (en) 2000-01-28
IL122161A (en) 1999-07-14
PT839132E (pt) 2001-06-29
IN185276B (cs) 2000-12-16
DE69611999D1 (de) 2001-04-12
EE03605B1 (et) 2002-02-15
HU220343B (hu) 2001-12-28
ATE199542T1 (de) 2001-03-15
UY24286A1 (es) 1997-01-17
AU6497896A (en) 1997-02-18
ZA966043B (en) 1997-02-03
SK5898A3 (en) 1998-08-05
CZ12298A3 (cs) 1998-12-16
CN1087289C (zh) 2002-07-10
EP0839132B1 (en) 2001-03-07
NO980209L (no) 1998-01-16
DK0839132T5 (da) 2006-03-20
PL191017B1 (pl) 2006-03-31
US6274740B1 (en) 2001-08-14
KR19990029045A (ko) 1999-04-15
KR100400805B1 (ko) 2003-12-24
EE9700369A (et) 1998-06-15
GEP20002027B (en) 2000-04-10
PL324463A1 (en) 1998-05-25
HRP960312A2 (en) 1998-02-28
SK283204B6 (sk) 2003-03-04
EA000625B1 (ru) 1999-12-29
DK0839132T3 (da) 2001-04-09

Similar Documents

Publication Publication Date Title
HRP960312B1 (en) NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
HU9200253D0 (en) Process for the production of amino acid derivatves
HUT54275A (en) Fungicidal compositions comprising substituted amino acid amide derivatives and process for producing such compounds
PH30131A (en) Process for producing l-glutamic acid by fermentation
HUT60430A (en) Process for producing medical aerosol compositions
HUT70526A (en) Indole-2-carboxylic acid derivatives, process for producing thereof and pharmaceutical compositions comprising same compounds
HUP9900055A3 (en) 4-aryl-1-phenylalkyl-1,2,3,6-tetrahydropyridin -derivatives, process for producing them and pharmaceutical compositions containing them
AU636803B2 (en) Process for producing salt of amino carboxylic acid
AU8913091A (en) Process for producing amino carboxylic acid salt
HU9503801D0 (en) Substituted 4-phenyl-thiazol derviatives, process for producing them and pharmaceutical compositions containing them
HUP9602072A2 (en) Substituted cinnamic acid guanidines, process for producing them, and pharmaceutical compositions containing them
EP0551596A3 (en) Process for producing naphtalenedicarboxylic acid
HU9303030D0 (en) Process for preparation of l-5-(2-acetoxi-propionyl-amino)-2,4,6-trijodo-dichloro-isophtalic acid
HUP9602748A2 (en) Novel n-pyrimidinyl-sulfonamides, process for producing them and pharmaceutical compositions containing them
ZA964752B (en) Stable pharmaceutical compositions containing tiludronate hydrates and process for producing the pharmaceutical compositions
ZA966154B (en) Aminophenylphosphonic acid compounds process for preparing them and pharmaceutical compositions containing them
AU4259493A (en) Process for producing hydroxyalkane carboxylic acid amides
EP0861274A4 (en) CONTINUOUS METHOD FOR SYNTHESIS OF POLYASPARAGIC ACID
EP0469517A3 (en) Process for producing l-glutamic acid
EG20289A (en) Process for preparing of novel pharmaceutical compositions comprising 3- substituted 2-oxindole -1- corboximides
HU9202069D0 (en) Microbiological process for producing 5-hydroxi-pyrazine-carboxylic acid
HUT59419A (en) Process for producing amino acid derivatives
HU9400325D0 (en) Process for producing amino-ascorbic acid derivatives and pharmaceutical compositions containing them
AU2094997A (en) Process for producing substituted aromatic thiocarboxylic acid amides
AU2988692A (en) Novel process for preparing 4-amino-5-hexenoic acid

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20150701

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20160703